Kyowa Hakko Kirin returns rights to Busulfex to Otsuka

17 September 2012

Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has reached agreement on returning development and marketing rights for cancer drug Busulfex (busulfan) to Otsuka Pharmaceuticals (TYO: 4578), for use as a part of conditioning regimen prior to hematopoietic progenitor cell transplantation. As a result, Kyowa Hakko Kirin will receive 2 billion yen ($25.3 million).

Otsuka acquired rights to the drug from USA-based PDL Pharma for $200 million (The Pharma Letter December 24, 2007). Busulfex is currently developed and marketed by Kyowa Hakko Kirin in Japan and in six Asian countries and regions (China, Korea, Taiwan, Singapore, Malaysia and Thailand).

Kyowa Hakko Kirin had in-licensed the development rights and dealership within Japan and in Asian countries and regions. The contract will terminate as of March 31, 2013, and Kyowa Hakko Kirin will return the rights to Otsuka Pharmaceutical on April 1, 2013.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical